AstraZeneca Increases Drug Stockpile in Preparation for Hard Brexit
18 Luglio 2018 - 12:31PM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Wednesday that it is increasing
its stockpile of drugs in preparation of a hard Brexit.
A spokesperson for the U.K.-listed drug maker said the company
has already spent 40 million pounds ($52.8 million) in case of a
no-deal scenario.
The pharmaceutical major is increasing by 20% its stockpile of
drugs that it receives from Europe into the U.K., as well as those
that it manufactured in the country and exported to the European
Union. However, this only represents a small portion of its total
manufacturing, the majority of which is unaffected, the
spokesperson added.
A hard Brexit, where the U.K. doesn't reach a deal over its
future relationship with Europe, is expected to result in widescale
disruption to its import of products from the continent.
The company was responding to questions from Dow Jones following
a BBC Newsnight report on Tuesday.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
July 18, 2018 06:16 ET (10:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
